Clinigen Continues Strategic Shift
Clinigen divests global rights to four cancer support therapies in support of move to solidify services.
In its continued efforts to increase the company’s focus on its pharmaceutical services market, Clinigen has divested four cancer supportive care products from its brands portfolio to CNX Therapeutics, a specialty pharmaceutical company. Those products, Cardioxane®, Savene®, Totect® and Ethyol®, address side effects patients may experience when treated with other cancer therapies. The financial terms for the divestment were not disclosed. Earlier this year, Clinigen sold Proleukin® to Iovance Biotherapeutics.
It also divested its European-based contract development business Lamda Laboratories SA, to Adragos Pharma GmbH. And late last year, Clinigen acquired Drug Safety Navigator, a specialist pharmacovigilance service provider based in the US.
The Clinigen services portfolio includes clinical trials sourcing, clinical supplies management, managed access and pharmacovigilance.
Jerome Charton, CEO of Clinigen, commented in a press release, “This divestment marks another milestone in Clinigen’s continued strategic evolution towards providing high-value services to the pharmaceutical and biotech sectors. These medicines have been integral to Clinigen, but as we refocus our efforts, it is crucial to align our offerings with our core strategy…”
Reference: “Clinigen divests global rights to four cancer support therapies to CNX Therapeutics,” 8/10/23. Clinigen press release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
